attem / Shutterstock.com
Pharmaceutical company Gilead Sciences has settled its patent dispute with Indian-based rival Natco Pharma over an attempt to market a generic version of its Tamiflu (oseltamivir phosphate) product.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead; Natco Pharma; Tamiflu; ANDA; US FDA; US Court of Appeals for the Federal Circuit; US District Court for the District of New Jersey
